Andere talen Trevi Therapeutics, Inc.

Aandelen

TRVI

US89532M1018

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,85 ^USD	-3,06%		+10,47%	+112,69%

20/03	Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
20/03	Trevi Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference	10/04
Trevi Therapeutics to Participate in Upcoming April Events	04/04
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team	02/04
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates	20/03
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024	13/03
Trevi Therapeutics to Participate in Upcoming March Events	28/02
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Trevi Therapeutics Provides Business Updates	04/01
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis	06/12
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)	05/12
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	05/12
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update	09/11
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough	03/11
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough	02/11
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough	02/11
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023	01/11
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis	16-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Trevi Therapeutics, Inc.

Aandelen

TRVI

US89532M1018

Andere talen

Filters